274 related articles for article (PubMed ID: 15695335)
1. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.
Tang TS; Slow E; Lupu V; Stavrovskaya IG; Sugimori M; Llinás R; Kristal BS; Hayden MR; Bezprozvanny I
Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2602-7. PubMed ID: 15695335
[TBL] [Abstract][Full Text] [Related]
2. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
4. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease.
Fernandes HB; Baimbridge KG; Church J; Hayden MR; Raymond LA
J Neurosci; 2007 Dec; 27(50):13614-23. PubMed ID: 18077673
[TBL] [Abstract][Full Text] [Related]
6. Deranged neuronal calcium signaling and Huntington disease.
Bezprozvanny I; Hayden MR
Biochem Biophys Res Commun; 2004 Oct; 322(4):1310-7. PubMed ID: 15336977
[TBL] [Abstract][Full Text] [Related]
7. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
8. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.
Shehadeh J; Fernandes HB; Zeron Mullins MM; Graham RK; Leavitt BR; Hayden MR; Raymond LA
Neurobiol Dis; 2006 Feb; 21(2):392-403. PubMed ID: 16165367
[TBL] [Abstract][Full Text] [Related]
9. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.
Bezprozvanny I
Subcell Biochem; 2007; 45():323-35. PubMed ID: 18193642
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
11. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease.
Zeron MM; Fernandes HB; Krebs C; Shehadeh J; Wellington CL; Leavitt BR; Baimbridge KG; Hayden MR; Raymond LA
Mol Cell Neurosci; 2004 Mar; 25(3):469-79. PubMed ID: 15033175
[TBL] [Abstract][Full Text] [Related]
14. Ca(2+) handling in isolated brain mitochondria and cultured neurons derived from the YAC128 mouse model of Huntington's disease.
Pellman JJ; Hamilton J; Brustovetsky T; Brustovetsky N
J Neurochem; 2015 Aug; 134(4):652-67. PubMed ID: 25963273
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.
Wu J; Tang T; Bezprozvanny I
Neurosci Lett; 2006 Oct; 407(3):219-23. PubMed ID: 16959411
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease.
Wu J; Ryskamp D; Birnbaumer L; Bezprozvanny I
J Huntingtons Dis; 2018; 7(1):35-50. PubMed ID: 29480205
[TBL] [Abstract][Full Text] [Related]
17. Tetrahydrocarbazoles decrease elevated SOCE in medium spiny neurons from transgenic YAC128 mice, a model of Huntington's disease.
Czeredys M; Maciag F; Methner A; Kuznicki J
Biochem Biophys Res Commun; 2017 Feb; 483(4):1194-1205. PubMed ID: 27553284
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Dimebon in cellular model of Huntington's disease.
Wu J; Li Q; Bezprozvanny I
Mol Neurodegener; 2008 Oct; 3():15. PubMed ID: 18939977
[TBL] [Abstract][Full Text] [Related]
19. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1.
Tang TS; Tu H; Chan EY; Maximov A; Wang Z; Wellington CL; Hayden MR; Bezprozvanny I
Neuron; 2003 Jul; 39(2):227-39. PubMed ID: 12873381
[TBL] [Abstract][Full Text] [Related]
20. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
Alto LT; Chen X; Ruhn KA; Treviño I; Tansey MG
PLoS One; 2014; 9(5):e96544. PubMed ID: 24824433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
